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Abbreviations  
BCLC   Barcelona Clinic Liver Cancer  
95% CI  95% confidence interval  
CRC  Colorectal cancer 
EASL  European Association for the Study of the Liver  
EBRT  External beam radiation therapy  
GDA  Gastroduodenal artery 
GI  Gastrointestinal 
HCC   Hepatocellular Carcinoma  
LS  Lung shunt  
LMWH Low molecular weight heparin 
MAA  Macroaggregated albumin   
MDT   Multidisciplinary team  
MRI   Magnetic Resonance Imaging  
PVT   Portal venous thrombosis  
REILD  Radioembolisation-induced liver disease 
SBRT  Stereotactic body radiation therapy   
SIRT  Selective internal radiation therapy 
SORAMIC  Evaluation of Sorafenib in combination with local micro-therapy guided   
  by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular  
  carcinoma  
SPECT Single-photon emission computed tomography  
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SIRFLOX Randomised phase III trial comparing first-line mFOLFOX6 ± bevacizumab  
  versus mFOLFOX6 + selective internal radiation therapy ± bevacizumab  
  in patients with metastatic colorectal cancer  
SIRTACE SIR-Spheres® microspheres versus transarterial chemoembolisation in   
  patients with unresectable hepatocellular carcinoma 
SOS  Sinusoidal obstruction syndrome  
TACE   Trans-arterial chemoembolisation  
TIPS  Transjugular intra-hepatic portosystemic stent-shunt  
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ABSTRACT 
 
Selective internal radiation therapy (SIRT or radioembolisation) by intraarterial injection of 
radioactive yttrium-90 (
90
Y)-loaded microspheres is increasingly used for the treatment of 
patients with liver metastases or primary liver cancer. The high-dose beta-radiation penetrates an 
average of only 2.5 mm from the source so that its effects are limited to the site of delivery. 
However the off-target diversion of 
90
Y microspheres to tissues other than the tumor may lead to 
complications. The most prominent ones include: radiation gastritis and gastrointestinal (GI) 
ulcers, cholecystitis, radiation pneumonitis, and radioembolisation-induced liver disease 
(REILD). Complications may occur despite careful pre-treatment planning and SIRT demands an 
expert multidisciplinary team (MDT) approach in order to provide comprehensive care for 
patients. This review provides recommendations to MDTs on the optimal medical processes in 
order to ensure the safe delivery of SIRT.  Based on the best available published evidence and 
expert opinion, we recommend the most appropriate strategies for the prevention, early diagnosis 
and management of potential radiation injury to the liver and to other organs. 
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INTRODUCTION 
Selective internal radiation therapy (SIRT, also known as radioembolization), involves the 
implantation of radiation sources into tumours using radioactive microspheres. Based on 
published evidence, this procedure is now widely available in specialist centres for the treatment 
of patients with liver metastases or primary liver cancer. There are two approved products 
available across continents using either glass or resin microspheres. Once administered into the 
hepatic artery that feeds liver tumours, they become permanently lodged in the terminal 
arterioles of tumour where the emitted high dose beta radiation is delivered locally. The off-
target diversion of 
90
Y microspheres to tissues other than the tumour may lead to complications. 
The most prominent ones are gastrointestinal (GI) ulcers, radiation pneumonitis, and 
radioembolisation-induced liver disease (REILD). The aim of this review is to provide 
recommendations to MDTs on the most appropriate strategies for the prevention, early diagnosis 
and management of potential radiation injury, based on the best available published evidence and 
expert opinion. 
 
METHODS 
Recommendations were developed by a panel of experts with extensive experience with SIRT, 
representing the relevant medical disciplines: medical oncology, interventional radiology, 
hepatology, radiation oncology and nuclear medicine. The methodology used for the systematic 
search of the literature and panel discussion of findings and recommendations is available online. 
In brief, the literature published between January1990 and June 2016 was systematically 
searched. A directed appraisal identified 196 papers that were reviewed in detail. An in-depth 
analysis was performed by complication and all authors had an opportunity to comment on each 
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recommendation. A number of recommendations involving technical aspects of the 
interventional radiology procedures are beyond the scope of this journal and will be discussed 
elsewhere.  
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RADIATION PNEUMONITIS 
The medical problem  
Radiation pneumonitis is a very rare but worrisome complication that may occur 1 to 6 months 
after SIRT and is characterised by the appearance of restrictive ventilatory dysfunction and 
bilateral lung infiltrates (1, 2) usually with exertional dyspnoea and dry cough. Only six cases (2, 
3) have ever been reported in detail, none of which were from clinical trials, and of these, 3 were 
fatal events in a single centre (3).  
 
Microspheres can circumvent the liver sinusoidal network through the tumour or through 
arteriovenous channels present in the cirrhotic liver, and ultimately reach the lung filter. During 
the pre-treatment work-up, technetium-99m macroaggregated albumin (MAA) is injected into 
the hepatic arteries. The lung shunt (LS) is estimated based on the fraction of MAA which 
becomes deposited in the pulmonary vasculature. The risk of pneumonitis arises when LS 
exceeds 10% (3) and is particularly high when it exceeds 20%. Treatment-limiting LS fractions 
>20% are atypical, but more common in HCC than other liver tumours (14% vs 3%) (4).  
 
The relevance of subclinical lung damage as a determinant of future cancer treatment is 
unknown. Further radiation exposure to the lungs is not recommended within 6 months of SIRT.  
Anecdotal evidence suggests that in cases where a second SIRT procedure is administered within 
6-12 months of the first, the maximum tolerated dose in lung should be <50% of the dose 
delivered to the lungs during the first procedure (5).  
 
Prevention of pneumonitis 
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Dose reductions of 20% and 40% are recommended by the manufacturer of resin microspheres if 
LS exceeds 10% or 15%, respectively and SIRT is contraindicated if the lung shunt exceeds 
20%. Strict adherence to these limits largely prevents this complication with no reported cases in 
recent multicentre retrospective analyses of 606 patients with metastatic colorectal cancer 
(mCRC) (6), 325 patients with HCC (7) and 112 patients with various tumour types (8).  For 
glass and resin microspheres, an upper limit of 30 Gy to the lung has been empirically 
established and again shown to largely prevent this complication. Yet, this dosimetric approach 
has several pitfalls. There are no reliable methods for assessing the real dose of radiation 
delivered to the lung, a normal tissue complication probability analysis for lung damage is 
lacking for SIRT, and dosimetric models do not consider functional lung volume.  Indeed, 
pneumonitis may rarely occur in patients with LS < 20% even if the dose threshold of 30 Gy is 
not reached, as illustrated in Figure 1. No drug has shown a positive effect in preventing lung 
damage produced by EBRT. Therefore, prevention of SIRT-induced pneumonitis by medical 
therapy is not available. 
 
LS is also important because a lower delivered tumour dose will also diminish efficacy. When 
LS is ≥15%, the SIRT team should strongly consider an alternative treatment approach rather 
than reducing calculated activity of 
90
Y delivered, or alternatively refer the patient to, or discuss 
the case with, a centre with high-volume experience. 
 
Diagnostic work-up for suspected pneumonitis 
If lung uptake is observed in imaging procedures following SIRT, we suggest checking the 
oxygen saturation by pulse oximetry or perform a 6-minute walk test on a weekly or bi-weekly 
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basis, and have a chest CT scan done in case of oxygen desaturation or dyspnoea. Similarly, any 
patient with a LS >10% that presents with dyspnoea within the first 3 months after SIRT should 
have a chest CT. If the characteristic bilateral symmetric ill-defined patchy opacities and ground-
glass nodularity with relative peripheral/hilar sparing (3) are observed and an infectious or 
cardiac cause can be ruled out, it is worth starting therapy without delay. Functional tests show a 
restrictive pattern with an altered diffusing capacity of the lung for carbon monoxide (DLCO).  
The decision to perform a broncho-alveolar lavage and/or a transbronchial lung biopsy should be 
based on the likelihood of alternative diagnosis that may be identified with these procedures.  
 
Treatment of pneumonitis 
Steroids form the mainstay of treatment (Table 1) although there is little supporting evidence.  
The patient may receive steroids for a minimum period of two weeks followed by slow tapering 
(9). Oxygen supply may be needed and treatment may be augmented with pentoxifylline, again 
on a totally empiric basis (3).  
 
 
GASTROINTESTINAL ULCERATIONS 
The medical problem   
Radiation-induced GI ulcerations are an uncommon complication of SIRT that presents usually 
2-6 weeks after SIRT with symptoms of acute epigastric pain, nausea, vomiting, dyspepsia and 
sometimes anorexia (10). Ulcers are usually multiple (0.5-2 cm in size), but can also be 
‘‘diffuse’’ and unmeasurable (11) and often associated with diffuse mucositis (12).  They 
typically have a chronic, insidious course with symptoms persisting for weeks despite 
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appropriate therapy.  In the largest clinical trial on SIRT, the incidence of GI ulcers was 2.4% 
among patients with mCRC (13). Several retrospective analyses of large cohorts reported a 
similar incidence of 1.9-3.2% (6, 7, 11, 14-16). The natural history has been described in detail 
(12). Symptoms are usually mild-to-moderate and last for 4-10 months despite treatment, but full 
symptomatic and endoscopic recovery normally occurs as shown in Figure 2. Complications 
include: pyloric stricture, haemorrhage, severe anaemia with transfusion needs, bilioenteric 
fistula, and death (7, 11, 12, 17). 
 
90
Y microspheres can be found in gastric biopsies obtained months to years after SIRT in 
asymptomatic patients. The administration of agents with a potential to produce gastric injury to 
these patients with subclinical GI damage may pose some theoretical concern, particularly 
antiangiogenics. Among patients with mCRC treated with SIRT plus FOLFOX in a large trial, 
the rate of bleeding or GI ulcers was reassuringly similar in those that received bevacizumab and 
those that had not (13).  
 
 
Prevention of GI ulcers 
Prevention of GI complications in SIRT largely depends on the identification of the vascular 
anatomy that allows microspheres injected into the hepatic arteries to gain access to the stomach 
or duodenum. A comprehensive evaluation of the liver arterial vasculature, careful evaluation of 
any MAA uptake that may be located outside the liver, the judicious use of coil embolization of 
collateral vessels to manage parasitisation/collateralisation, and the prevention of stasis and 
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reflux during infusion should minimize the risk of GI ulcers. Yet, they can still occur due to 
unnoticed or recanalised collateral vessels or changes in flow dynamics during treatment. 
 
Although commonly used, there is no scientific evidence to support the use of proton pump 
inhibitors (PPI) in the prevention of radiation-induced damage to the GI tract. Routine PPI 
therapy should not therefore be considered mandatory.  If PPI are prescribed, they should be 
maintained for at least 8 weeks, when SIRT-related GI ulcers usually become symptomatic. 
Other prophylactic approaches including the use of the prostaglandin E2 inhibitor, misoprostol, 
or the identification and eradication of Helicobacter pylori prior to SIRT may be considered, but 
equally lack supporting scientific evidence. 
 
The detection of extrahepatic uptake of radioactivity in post-SIRT imaging procedures that is 
consistent with GI exposure to radiation deserves special consideration. The limitations in space 
resolution of these imaging techniques, including but not only the effect of respiratory 
movements, may produce false positive observations. The use of prophylactic PPI is generally 
recommended, but gastroscopy does not need to be performed in the absence of significant 
symptoms. The use of innocuous radioprotective agents such as amifostine might be considered 
in some cases (18). 
 
Diagnostic work-up for suspected GI ulcerations 
An upper endoscopy should be performed in every patient who develops persistent upper 
abdominal pain 4 to 8 weeks after SIRT, particularly if pain is associated with nausea, loss of 
appetite or anaemia. Early gastroscopy is also encouraged for those patients in whom anaemia 
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develops or worsens 4-6 weeks after SIRT. Failure to retrospectively detect extrahepatic uptake 
of radioactivity in the post-SIRT scans in these patients should not lead to delayed evaluation. 
The presence of multiple mucosal erosions and ulcerations or a single large ulcer, usually 
associated with diffuse mucositis, and the distribution of the lesions, usually involving the distal 
gastric body, antrum, pylorus and the duodenal bulb, allow the presumptive diagnosis (10, 12, 
19-23). The poor healing of the radiated site often discourages regular biopsies that will unlikely 
change patient management.  
 
Treatment of GI ulcerations 
Radiation-induced GI ulceration is poorly responsive to therapy but the most relevant 
recommendations are summarised in Table 2.  Mild-to-moderate symptoms can be treated by 
dietary modification and starting or increasing to maximal the dose of PPI, the gastroprotective 
agent Sucralfate, antiemetics, analgesics, and gastric promotility agents such as Domperidone or 
Cinitapride (12). Nonsteroidal anti-inflammatory drugs and any other medication potentially 
harmful for the GI mucosa have to be withdrawn. In more severe cases, pain and nausea relief 
can only be achieved by total parenteral nutrition. When the situation persists for weeks, 
jejunostomy may provide long-term symptom control until ulcers heal and secure proper 
nourishment (23). Recurrent GI haemorrhage can be managed by direct endoscopic therapy or 
selective bland targeted arterial embolisation. Rarely (less than 10% of cases), perforation or 
bleeding may require surgical excision of the involved GI tract segment with bypass (24, 25).  
 
LIVER COMPLICATIONS  
The medical problem  
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Identifying liver toxicity in patients with liver cancer treated with liver-directed therapies is not 
an easy task. The liver that harbours a cancer is by definition non-healthy. Patients with primary 
liver cancer usually have a chronic liver disease frequently in the cirrhotic stage. Those with liver 
metastases from distant cancers quite commonly have steatosis or fibrosis either at diagnosis or 
after exposure to several chemotherapeutic agents, including oxaliplatin, irinotecan or 
fluoroderivatives (26).  Tumour growth in the liver may per se ultimately impair liver functions. 
On the other hand, the liver is a multifunctional organ and different variables may reveal liver 
dysfunction, from laboratory values to organ rigidity to distant signs of portal hypertension.  
 
Radioembolisation-induced liver disease (REILD) 
REILD is a well-defined syndrome characterised by the appearance of jaundice and ascites 4 to 8 
weeks after SIRT in the absence of tumour progression or bile duct occlusion (27).  REILD is 
always associated with elevated bilirubin (> 3mg/dL) with variable increases in alkaline 
phosphatase and gamma-glutamyl transferase (GGT), and virtually no changes in transaminases 
(AST and ALT).  This syndrome is clinically distinct from the anicteric ascites caused by EBRT 
(28).  REILD resembles other forms of sinusoidal obstruction syndrome (SOS). Indeed in the 
most severe cases liver biopsy shows veno-occlusive disease, the histological hallmark of SOS 
(27, 29). Importantly, SOS may also occur in CRC patients that receive oxaliplatin- or 
irinotecan-based regimes (30), which is the clinical setting for many SIRT-treated patients. 
 
REILD is an uncommon event. Incidence rates of 5.4% (31) and 4% (32) have been reported on 
large series with a mix of tumour types. REILD appears mainly, if not exclusively, in two 
groups: non-cirrhotic patients exposed to systemic chemotherapy prior to SIRT and treated in a 
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whole liver-fashion because of extensive tumour load (e.g. colorectal or breast cancer patients 
treated in a salvage setting), and patients with cirrhosis and reduced liver functional reserve, even 
if treated in a more selective fashion (e.g. patients with HCC) (31). The risk of REILD is 
increased if patients are exposed to chemotherapy in the 2-month period following SIRT (31), in 
the presence of a small liver (total volume <1.5 L)(31) or increased baseline bilirubin and AST 
(31), after an intense treatment (16, 31), and with repeated whole-liver SIRT (16). In many 
patients, the disease may be controlled by therapy, but severe complications including overt liver 
failure may rapidly ensue (33). Although there are no reports on prospective long-term follow-up 
of patients with REILD, median survival as short as 95 days from SIRT has been reported (32). 
For any SIRT centre, the outcomes of a regular review and/or an audit process are essential to 
identify whether complication rates are within the expected limits reported in the recent literature 
(6, 31). There is no clear indication that the occurrence of REILD is different for resin or glass 
microspheres although the highest incidence of liver decompensation (36.5% at 6 months) has 
been reported after SIRT using glass microspheres in intermediate or advanced HCC patients 
(34).  
 
SIRT may produce subclinical liver injury. A significant although clinically irrelevant increase in 
total bilirubin has been reported in CRC (35), breast cancer (36), and HCC (37) patients. The 
implications of this subclinical liver damage on the tolerability of subsequent treatments are not 
known and require further investigation in well designed, prospective studies.   
 
Portal hypertension 
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Non-cirrhotic portal hypertension may very rarely develop months to years after SIRT. Early 
asymptomatic increases in splenic volume with or without low platelet count are frequently 
observed, even after lobar SIRT (32, 36, 38).  Similar findings may be seen in patients treated 
with adjuvant FOLFOX for stage II-III CRC due to sinusoidal injury (39). Gastro-oesophageal 
varices have been anecdotally identified years after SIRT (40). Histological findings observed in 
these patients indicate nodular regenerative hyperplasia (unpublished data) with (40), or without 
(29) bridging fibrosis. Encephalopathy or variceal bleeding have not been reported in non-
cirrhotic patients. 
 
Biliary tree damage 
Biliary tree injury post-SIRT has been reported unfrequently, including bile duct necrosis or 
strictures.  Among 569 SIRT treatments in 327 patients, 3 patients (1%) developed large bilomas 
requiring drainage (41) while asymptomatic biliary necrosis and strictures were observed in 
3.9% and 2.4%, respectively. In this large series, biliary complications were more common in 
metastatic disease with multiple disseminated tumours than in primary HCC. Bile duct 
compression by tumours cannot be ruled out in many cases.  The consensus, based on expert 
opinion, is that SIRT is unlikely to be the primary cause of isolated biliary strictures. This is 
partially supported by recent evidence of minimal or no significant biliary complications with 
SBRT or high-dose hypofractionated radiation therapy for tumours located within the perihilar 
region (42-44). Ischemic cholangitis leading to diffuse biliary strictures has only once been 
reported after SIRT (45).  
 
Prevention of REILD 
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Patients with poor liver functional reserve as those that present with a total bilirubin >2 mg/dL or 
have non-tumoural ascites should not be considered candidates to SIRT. Individual yet 
conservative decisions should be made in patients with bilirubin values slightly below this 
threshold in which a rapid increase is observed within the weeks previous to SIRT evaluation. 
 
Adaptation of the calculated activity is recommended in all cases where patients may have a low 
functional liver reserve because of steatosis, steatohepatitis, hepatitis, or cirrhosis, where the 
liver is small (<1.5 L) and in patients who have received multiple lines of prior chemotherapy.  
Both the type and duration of prior systemic treatment are important, with anecdotal evidence, 
for example, that the more hepatotoxic therapies used for the treatment of breast cancer may 
increase the risk of REILD.  
 
The BSA formula is the recommended method for calculating the prescribed activity for SIRT 
using resin microspheres while for glass microspheres activity is calculated from the volume of 
liver that is targeted. There is general agreement that BSA formula may overestimate the activity 
and liver toxicity is lower when the prescribed activity is reduced (6). A tailored treatment 
protocol has recommended a dual strategy of either more selective lobar or segmental treatment 
(enabling a greater spared liver volume) or a reduction in the prescribed activity for patients 
receiving whole-liver SIRT (31). Tables that display a modified BSA formula according to 
tumour load and lung-shunt have been used in large clinical trials in CRC patients (13).  
 
Both for resin and glass microspheres, the development of reliable dosimetric methods for 
activity prescription represent the holy grail (5, 46, 47). Dosimetric analysis indicates that better 
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tumour responses are associated with higher mean absorbed doses. From the safety perspective, 
however, the use of dosimetric methods faces several problems including heterogeneous 
distribution of particles in the non-tumoural liver, potential changes in particle distribution 
between MAA and 
90
Y microsphere injections due to catheter position and local haemodynamic 
conditions (48), or suboptimal measurement of the tumour to non-tumour ratio for multinodular 
tumours. Such methods may, however, be reliable for prescribing the activity to patients 
receiving selective treatment if the tumour to non-tumour uptake ratios of 
90
Y-microspheres can 
be calculated accurately (31, 49). But they have not been validated in prospective trials and are 
not appropriate for whole-liver treatment, nor for tumours without significant uptake of MAA. 
 
Sequential lobar treatment (i.e. deferring treatment of the contralateral liver lobe for 6 weeks) 
may improve liver tolerance to SIRT for several reasons. By deferring subclinical liver injury in 
the contralateral lobe it may lower the likelihood of clinical decompensation. By increasing 
contralateral lobe volume it may reduce the relative intensity of treatment in that lobe. It provides 
clinicians with an opportunity to evaluate of the tolerability of SIRT and modify activity 
prescribed to the contralateral lobe.  And finally, the induction of hepatocyte growth factor and 
other pro-regenerative factors after lobar SIRT (37) might make the contralateral lobe more 
tolerant to SIRT (50). As a major counterpart, sequential lobar treatment increases treatment-
derived costs of an already costly therapy. Small case series have suggested that this approach 
resulted in fewer grade 3/4 toxicities and liver damage (51) but it has not proved to improve 
strong outcomes including overall survival. General recommendation should therefore await 
prospective validation and cost-economic analysis. 
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Prophylactic treatments such as pentoxifylline, ursodeoxycholic acid, and low molecular weight 
heparin (LMWH) have been evaluated to reduce the liver damage caused by conditioning total 
body irradiation regimens prior to bone marrow transplantation with equivocal results (52-54). 
Pentoxifylline prevents activation of stellate and endothelial cells by interfering with TGF-beta 
signalling; LMWH may prevent thrombosis; and ursodeoxycholic acid protects endothelial cells 
from injury (55) and hepatocytes from cytokine-induced damage (56) while it is known that 
SIRT is followed by a systemic inflammatory response (37).  
 
Building on this concept, the combination of ursodeoxycholic acid (300 mg twice daily) and 
methylprednisolone (8 to 4 mg once a day) was incorporated into a tailored treatment protocol 
that also included changes in the algorithm for activity calculation. Prophylactic drug therapy 
was not independently predictive of the reduced incidence of liver decompensation. In a recent 
small prospective study, the incidence of focal radiation-induced liver damage at 6 weeks was 
significantly lowered when patients were treated with pentoxifylline, ursodeoxycholic acid and 
low-dose LMWH after image-guided interstitial brachytherapy for lmCRC (57). Although 
ursodeoxycholic acid and low-dose steroids are generally innocuous, currently there is 
insufficient evidence to recommend prophylactic medication to reduce the incidence of REILD 
after SIRT.  
 
Recommended diagnostic work-up for suspected REILD 
REILD has to be considered in any patient, cirrhotic or not, that develops jaundice and ascites 
within the first 3 months after SIRT. Patients may be instructed to provide the result of blood 
tests including total bilirubin, alkaline phosphatase and transaminases 4 to 6 weeks post-SIRT, as 
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well as to report on the presence of oedema or abdominal swelling. Upon the discovery of 
bilirubin >3 mg/dL, the physician should request an abdominal ultrasound to rule out bile duct 
obstruction and to confirm the presence of ascites and the patency of the portal and hepatic veins, 
as well as additional blood test to measure liver function including albumin and coagulation 
factors (at least prothrombin activity). Other laboratory tests such as viral hepatitis markers 
should be ordered in case of markedly elevated AST/ALT (>1000 IU/mL) or if clinically 
advised.  Contrast-enhanced CT or better MRI scan is recommended to accurately evaluate intra- 
and extra-hepatic tumour progression. If the diagnosis is not obvious based on the result of tests 
and imaging procedures and the course of the disease is stable or worsening, an early liver 
biopsy is strongly recommended because it may guide treatment. Biopsy is not recommended for 
cirrhotic patients since the histological findings may be equivocal (27) and there is increased risk 
of bleeding. Once the diagnosis of REILD is established, liver function tests should be repeated 
(at least weekly) to identify those patients that may be in transit to liver insufficiency, with 
declining coagulation and increasing bilirubin. 
 
Treatment of REILD 
Table 3 summarises the most relevant recommendations. Initial symptomatic therapy should 
include diuretics (low-dose spironolactone and/or furosemide). Defibrotide, a single-stranded 
polydeoxy-ribonucleotide with antithrombotic, thrombolytic, anti-inflammatory and anti-
ischaemic properties has been successfully used in veno-occulsive disease post-stem cell 
transplantation at doses ranging from 10 to 40 mg/kg over a median of 18 days (58, 59).  Based 
on this experience, treatment with defibrotide may be considered in patients with REILD and 
rapidly increasing bilirubin (>6 mg/dL) or an altered coagulation (decline in prothrombin activity 
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with or without low platelet count).  If medical treatment is ineffective, prompt transjugular 
intra-hepatic portosystemic stent-shunt (TIPS) placement is recommended as a potentially life-
saving procedure for patients with ongoing decline in liver function following SIRT.  This 
recommendation is based on largely anecdotal experience with REILD (27) and the collective 
published literature in life-threatening clinical syndromes resulting from sinusoidal congestion 
(60, 61).  
 
RADIATION CHOLECYSTITIS. 
The medical problem 
Acute cholecystitis is a rare complication of SIRT. Symptoms are characterised by upper right 
quadrant abdominal pain, nausea or vomiting, malaise and occasionally, fever. On the other 
hand, a thickened gallbladder wall is occasionally observed in patients that remain 
asymptomatic. In a detailed analysis of CT changes in the gallbladder following SIRT, 
thickening and hyper-enhancement of the gallbladder wall was observed in 10 out of 42 patients 
(90% had metastases adjacent to the gallbladder).  These features were most prominent on the 
first follow-up scan at 20-30 days after treatment (62). The incidence and natural history of 
gallbladder toxicity are largely unknown, but less than 10 cases of acute cholecystitis have been 
reported in the literature, and only five in detail (63, 64). Surprisingly, in 4 out of these 10 cases, 
review of MAA and 90Y SPECT images did not reveal increased radioisotope uptake in the 
gallbladder (64). Cholecystectomy was performed in 7 of these patients without any serious 
complication (41, 63-65). 
 
Critical assessment of current recommendations for prevention of cholecystitis 
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Gallbladder imaging changes are largely asymptomatic, but the deposition of 90Y-microspheres 
in the gallbladder should also be avoided to maximise the delivery of microspheres to the target 
tumour tissue. As a general rule, placement of the catheter distal to the cystic artery is 
recommended and only if this is not feasible, temporary occlusion of the cystic artery may be 
performed preferably immediately before SIRT injecting Gelfoam particles (66) or inducing a 
vasospasm of the cystic artery using a microwire (67). Coil embolisation of the cystic artery 
(which may induce acute ischemic cholecystitis (68)) or preventive cholecystectomy are not 
recommended.  
 
Relevance of subclinical damage to the gallbladder  
On imaging, some shrinkage of the gallbladder may be evident 6 months post-SIRT, but this is 
not thought to be clinically significant. 
 
Prevention by medical therapy of acute cholecystitis 
Empiric preventative measures using steroids and antibiotics in patients judged to be at risk of 
cholecystitis (based on scans during the pretreatment work-up) (67) are not recommended.  
 
Recommended diagnostic work-up for radiation cholecystitis 
Radiation cholecystitis should be suspected in any patient that develops persistent right upper 
quadrant tenderness and fever 4- to 6-weeks following SIRT.  The presence of a thickened 
(≥3.5mm) wall with pericholecystic fluid, intramural gas or hydrops on ultrasound, MRI or CT 
helps confirm the diagnosis. A thickened, hyper-enhanced gallbladder wall alone should not 
prompt a diagnosis of cholecystitis in the absence of consistent signs on physical examination, 
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including Murphy’s sign. If re-evaluation of the MAA scan, Brehmsstralung SPECT scan or 
90Y-PET reveals no evidence of intense gallbladder uptake, cholecystitis is highly unlikely. In 
such cases, an upper endoscopy may be needed to differentiate cholecystitis from gastric and 
duodenal ulcerations.  
 
Recommended treatment for radiation cholecystitis 
As summarized in Table 4, conservative therapy includes IV hydration and analgesics, while 
steroids are not recommended. Patients with fever, intense pain, or signs of wall necrosis or 
rupture on imaging should be considered for cholecystostomy (drainage of the gallbladder) 
and/or cholecystectomy. Cholecystectomy is the mainstay of the treatment of acalculous 
cholecystitis but patients who are critically ill or at high risk for surgical complications are better 
managed by percutaneous cholecystostomy and eventually delayed cholecystectomy. In cancer 
patients, incorporation of the surgical risk and the patient-specific survival and the impact of 
antineoplastic therapy in the decision making process may be beneficial (69). 
 
OTHER POTENTIAL COMPLICATIONS 
In a minority of patients, SIRT can be followed by acute symptoms during or shortly after 
infusion that resemble the post-embolization syndrome observed after TACE and is probably due 
to the embolizing nature of the radioactive beads. In large series of HCC and CRC patients, 
reported rates are 13-39% for abdominal pain, 2-12% for fever and 17-32% for nausea and/or 
vomiting (7, 70-72). They are usually mild, last for a few hours and are easily managed by 
medical treatment including non-narcotic analgesics (paracetamol 1 g with or without codeine 
phosphate 30-60 mg orally or IV) or ondansetron (8 mg orally or IV).  
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There is no strong published evidence that patients with a “violated ampulla” due to stenting, 
papillotomy or surgical biliary bypass are at increased risk of infectious complications. 
Nevertheless, these patients are usually considered as having a relative contraindication to SIRT 
and are therefore underrepresented in large cohorts.  The expert consensus is that biliary tree 
instrumentation should not be considered an absolute contraindication for SIRT but treatment 
should not be conducted in patients with a history of previous sepsis or biliary drainage without 
prophylactic antibiotics. 
 
Initially, there was a concern that SIRT might increase the morbidity of subsequent liver 
resection or transplantation. A specific study addressing this question in which 100 patients have 
been analysed (71 liver resections and 29 transplantations) has shown that the reported rates of 
complications do not differ much from what can be expected if the patients were operated 
without prior SIRT (73).  
 
CONCLUSIONS 
Selective internal radiation therapy is used to treat patients with primary and secondary liver 
cancer. The vast majority of patients have no or mild procedure-related symptoms. If a 
significant amount of radioactive particles reach non-targeted organs such as the lung, the GI 
tract or the gallbladder, the radiation may produce tissue damage. This will occur rarely if the 
procedure is performed to adequate quality assurance standards. However, a certain amount of 
radiation is always delivered to the non-tumoural liver tissue irrigated by the artery in which the 
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microspheres are administered. Again, this will only rarely lead to complications if the 
recommendations of the manufacturers are followed to calculate the amount of radioactivity that 
should be injected. It should be noted that some patients have livers that are more sensitive to 
radiation or have a reduced liver functional reserve and they are at greater risk of clinically 
significant tissue damage. The impact of radiation-induced tissue damage on patient's health 
ultimately depends of the damage induced by the treatment and, quite importantly, in the 
relevance of the organ involved. Pneumonitis is a potentially fatal but exceptionally rare 
complication.  REILD is uncommon but also potentially life-threatening. GI ulcers and 
cholecystitis may impact quality of life but generally have less severe implications. 
 
Local practices used to prevent and treat such complications vary between centres. In this article, 
we have extensively analysed the literature to identify the incidence, natural course and risk 
factors for all these main four complications as well as the relevance of subclinical damage to the 
corresponding tissues. Based on the available evidence, we have provided recommendations and 
proposed new medical approaches. Specific recommendations have been made for the diagnostic 
work-up and treatment of complications induced by SIRT. We believe that this expert guidance 
may help multidisciplinary teams and individual physicians to make sound decisions with the 
aim of improving care for patients with primary and secondary malignancies of the liver. 
 
REFERENCES 
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
  
  
This article is protected by copyright. All rights reserved.
Figure legends 
Figure 1. Superselective SIRT was indicated in a patient with hepatocellular carcinoma that had 
a 27 % lung shunt fraction based on pre-treatment MAA scan (A). A dose of 0.5 GBq of resin 
microspheres was prescribed that should have resulted in an estimated dose of radiation to the 
lungs of 7 Gy. A higher exposure was suspected based on the post-SIRT Brehmsstralung-SPECT 
images (B). Cough, dyspnea and hypoxemia developed 22 days after SIRT. Chest X-ray (C) and 
CT scan (D) showed the typical pattern of radiation pneumonitis, which was fatal in this case. 
 
Figure 2.  A 39-year-old patient with liver metastases from a pancreatic neuroendocrine tumor 
developed extensive GI ulcerations 4 weeks after SIRT (A) through the left hepatic artery. 
Clinical symptoms took more than 3 months to resolve, but complete healing was observed at 
month 12. The patient remains symptomless and with no relevant gastric abnormalities 8 years 
later (B).  
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Table 1. Expert advice on prevention, diagnostic work-up and treatment of radiation pneumonitis 
 
Prevention Work-up Treatment 
Reductions of 20%, 40% and 
100% in injected activity if lung 
shunt exceeds 10%, 15% or 
20%, respectively (for resin 
microspheres). 
 
Dose of radiation to lung tissue 
under 30 Gy based on MAA 
scan (for resin or glass 
microspheres). 
 
If lung shunt is ≥ 15%, strongly 
consider an alternative 
treatment approach (balance 
between safety and efficacy). 
 
 
Chest CT scan if hypoxemia, 
cough or dyspnoea within the 
first 2 months post-SIRT, 
particularly if lung shunt on 
MAA scan was >10%. 
 
Functional tests to confirm 
restrictive pattern and altered 
carbon monoxide diffusion level 
(DLCO). 
 
The decision to perform a 
broncho-alveolar lavage and/or 
a transbronchial lung biopsy 
should be based on the 
likelihood of alternative 
diagnosis. 
Steroids on a very empiric basis 
(methylprednisolone 500 mg IV bid 
or prednisolone 60 mg PO and 
slow tapering).  
 
Oxygen supply as needed. 
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Table 2. Expert advice on prevention, diagnostic work-up and treatment of radiation-induced GI ulcers 
Prevention Work-up Treatment 
Conventional or CT angiography 
to identify hepaticoenteric 
vessels, and avoid them by coil 
embolization, a more distal 
injection or flow redistribution. 
 
SIRT simulation using MAA test 
with 
 Perchlorate to avoid false 
positive gastric uptake. 
 MAA prepared within 30 
minutes before injection. 
 Injection from the same 
site as treatment. 
 SPECT imaging performed 
within 1 hour after 
injection. 
  
If a false-positive result is 
suspected, repeat MAA test 
before contraindicating SIRT.  
 
Use isotonic dextrose 5% as the 
administrative agent for resin 
microspheres. 
 
IA lidocaine or nitroglycerine may 
ameliorate vasospasm during 
SIRT. 
 
Upper endoscopy in every 
patient who develops upper 
abdominal pain 4 to 8 weeks 
after SIRT, particularly if 
associated with nausea, loss of 
appetite or anaemia (even if no 
extrahepatic uptake of 
radioactivity in the MAA 
SPECT/CT or 90Y-PET scans). 
 
Presumptive diagnosis based on 
gross morphology (multiple 
erosions and ulcerations or a 
single large ulcer, with diffuse 
mucositis, usually involving the 
distal gastric body, antrum, 
pylorus and the duodenal bulb).  
 
Biopsies not mandatory unless 
an alternative cause is 
considered. 
High-dose proton pump 
inhibitors (Omeprazole 40 mg 
daily or equivalent doses of 
Pantoprazole, Lansoprazole, etc), 
Sucralfate, antiemetics, 
analgesics, and gastric 
promotility agents 
(Domperidone or Cinitapride). 
 
Avoid nonsteroidal anti-
inflammatory drugs and any 
other medications that may 
produce gastritis or ulcers.  
 
In more severe cases consider 
total parenteral nutrition or 
jejunostomy. 
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Table 3. Expert advice on prevention, diagnostic work-up and treatment of REILD 
Prevention Work-up Treatment 
Contraindicate if total bilirubin 
>2mg/dL or non-tumoural 
ascites. Consider individually late 
changes in bilirubin. 
 
Consider reducing the 
recommended activity for 
patients with chronic liver 
disease (including 
steatohepatitis or cirrhosis), 
where the liver is <1.5 L, and in 
patients who have received 
multiple prior chemotherapy 
regimes.   
 
Spare as many liver segments as 
appropriate and technically 
feasible. 
 
 
Suspect REILD in any patient 
that develops jaundice and 
ascites within the first 3 months 
after SIRT.  
 
Request US-doppler to check for 
bile duct obstruction, ascites, 
and portal/hepatic vein patency, 
plus blood test to measure liver 
damage and function (ASAT, 
ALAT, alkaline phosphatase, 
total bilirubin, albumin, INR). If 
bile duct obstruction is 
discarded, request contrast-
enhanced CT or (better) MRI to 
rule out tumor progression. 
 
Repeat LFTs at least weekly. If 
the problem persists or worsens 
within 2 weeks consider liver 
biopsy (only for non-cirrhotic 
patients) and consultation with 
Hepatologist. 
Treat initially with diuretics 
(Spironolactone 100 mg and/or 
Furosemide 40 mg daily) and 
adjust the dose based on weight 
loss and renal function.  
 
If liver function starts to decline 
(for instance, total bilirubin ≥ 6 
mg/dL and prothrombin activity 
≤ 60% or INR ≥ 1.4), consider 
Defibrotide IV at a starting dose 
of 10 mg/kg. 
 
If liver failure develops despite 
medical treatment, consider 
transjugular intra-hepatic 
portosystemic stent-shunt (TIPS) 
placement.  
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Table 4. Expert advice on prevention, diagnostic work-up and treatment of radiation cholecystitis 
Prevention Work-up Treatment 
When a significant amount of 
activity is likely to be diverted to 
the gallbladder and to maximise 
the delivery of microspheres to 
the tumour, place the catheter 
distal to the cystic artery.  
 
If this is not feasible, perform 
temporary occlusion of the 
cystic artery using microwire-
induced vasospasm or Gelfoam 
particles immediately before 
SIRT. 
 
 
Suspect radiation cholecystitis in 
any patient with persistent right 
upper quadrant tenderness 4- to 
6-weeks following SIRT.  The 
presence of a thickened (≥ 
3.5mm) wall with pericholecystic 
fluid, intramural gas or hydrops 
on imaging may confirm the 
diagnosis if there are consistent 
signs on physical examination 
(Murphy). 
 
Re-evaluation of Brehmsstralung 
SPECT scan or 90Y-PET to 
confirm gallbladder uptake of 
radiation is helpful. 
Provide IV hydration and 
analgesics on demand. 
Consider cholecystostomy 
(preferred) or cholecystectomy in 
patients with fever, intense pain, 
or signs of wall necrosis or 
rupture on imaging.  
 
Weight surgical risk, patient-
specific survival and the impact of 
antineoplastic therapy before 
taking a surgical decision.  
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